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Nonalcoholic fatty liver disease (NAFLD) is the most common cause of elevated liver function tests results, after the commonly
investigated causes have been excluded, and frequently coexists with type 2 diabetes mellitus (T2DM) because the conditions have
common risk factors. As both T2DM and NAFLD are related to adverse outcomes of the other, diagnosis and valuation of fatty
liver is an important part of the management of diabetes. Although noninvasive methods, such as biomarkers, panel markers, and
imaging, may support a diagnostic evaluation of NAFLD patients, accurate histopathological ﬁndings cannot be achieved without
a liver biopsy. As it is important to know whether steatohepatitis and liver ﬁbrosis are present for the management of NAFLD,
liver biopsy remains the gold standard for NAFLD diagnosis and evaluation. Therefore, new investigations of the pathogenesis of
NAFLD are necessary to develop useful biomarkers that could provide a reliable noninvasive alternative to liver biopsy.
1.Introduction
Fatty liver, or hepatosteatosis, is characterized histologically
by triglyceride accumulation within the cytoplasm of hep-
atocytes [1] and refers to fat accumulation in the liver
exceeding 5%–10% by weight [2]. When hepatosteatosis is
present in the absence of excessive alcohol consumption, it is
termed non-alcoholic fatty liver disease, or NAFLD [1, 3–5],
which is considered to be the hepatic manifestation of the
metabolic syndrome [1, 6, 7], a constellation of frequent
abnormalities involving insulin resistance, visceral obesity,
dyslipidemia, diabetes, hypertension, plus additional factors.
Hence,currenttherapeuticapproachesfocusontreatmentof
theunderlyingriskfactorsforthesemetabolicconditions[8].
NAFLD encompasses a spectrum of disorders ranging from
simple steatosis to inﬂammatory steatohepatitis (NASH) and
cirrhosis. Of those who develop NASH, about 20% of pa-
tients will develop cirrhosis during their lifetime [9]. There-
fore, a diagnosis of NASH may result in a more aggressive
therapeutic approach toward the metabolic risk factors [10].
In addition, a diagnosis of cirrhosis may suggest the need
for an assessment of any associated complications, such as
esophageal varices, hepatocellular carcinoma, and so on.
The prevalence of NAFLD in the general adult population
has been estimated to range from 10% to 24% worldwide;
and is as high as 57.5% to 74% in those who are obese
[11]. Currently, NAFLD is believed to account for up to
90% of all cases demonstrating elevated liver function test
(LFT) results in patients after the commonly investigated
causes have been excluded (e.g., viral hepatitis, alcoholism,
inherited liver disease, or medications) [11].
NAFLD and Diabetes. NAFLD and type 2 diabetes mellitus
(T2DM)frequentlycoexistbecausetheysharetheriskfactors
of excess adiposity and insulin resistance. The prevalence of
T2DM or impaired fasting glucose ranges from 18–33% in
patients with NAFLD, whereas it ranges from 49–62% in
T2DM patients who have NAFLD [12–15]. NASH is present
in 12.2% of patients with T2DM, as compared to 4.7%
in those without T2DM [16]. Moreover, T2DM increases
the risk of liver-related death by up to 22-fold as well as
overall death by 2.6–3.3-fold in patients with NAFLD [17].
In contrast, the presence of NAFLD among patients with2 Experimental Diabetes Research
T2DM can also be a risk factor for increased mortality; a
community-basedstudyofpatientswithT2DMrevealedthat
those with NAFLD had 2.2-fold increased risk of mortality
compared with those without NAFLD [18]. A recent article
also reported that the presence of NAFLD in T2DM patients
may also be linked to increased cardiovascular disease
(CVD) risk, independently of components of the metabolic
syndrome [19, 20], although Ghouri et al. pointed out in-
consistencies in the evidence among some articles [21].
Therefore, T2DM is a risk factor for progressive liver disease
and mortality in patients with NAFLD, whereas NAFLD
may be a marker of cardiovascular risk and mortality in
individuals with T2DM. Both T2DM and NAFLD are related
to adverse outcomes of the other. In addition, although type
1diabetesmellitus(T1DM)isduetoarelativelackofinsulin,
an increased prevalence of obesity and insulin resistance in
this population means that NAFLD commonly coexists in
patients with T1DM [22–25]. An association of NAFLD in
T1DM with an increased prevalence of CVD has also been
reported [25].
Hence, the diagnosis and evaluation of fatty liver is
an important part of the management of diabetes. When
diabetes patients are diagnosed with NAFLD, more intensive
monitoring and therapeutic intervention are necessary to
avoid a poor prognosis. The methods used for the diagnosis
and evaluation of NAFLD can also be used to monitor the
eﬃcacyofinterventionortherapy.Inthisreview,wedescribe
the current trends in the diagnosis and evaluation of NAFLD
based on recent articles.
2. Diagnosis andEvaluationof NAFLD
The diagnosis of NAFLD needs conﬁrmation of hepatic
steatosis based on either imaging studies or liver biopsy,
together with the clinical exclusion of individuals who
regularly consume >20g ethanol per day [26]. In the clinical
setting, there is still no consensus about whether or not liver
biopsy is required to conﬁrm a diagnosis of NAFLD [8].
Presently, the available noninvasive markers for NAFLD
include a set of clinical signs and symptoms, laboratory
tests, imaging tests, and combinations of clinical and blood
test results. Although several of these markers are, in gen-
eral, useful for the diagnostic evaluation of a patient with
suspected NAFLD, they lack the speciﬁcity and sensitivity to
distinguish NAFL from NASH and to determine the pres-
ence and stage of ﬁbrosis [10]. After a diagnosis of NAFLD,
the next step is to determine the severity, and this infor-
mation is necessary to understand the prognosis. Although
noninvasive diagnostic methods have advanced recently, a
liver biopsy is still required to determine the severity of
NAFLD. When staging patients with NAFLD, there are two
factors related to the severity: the level of ﬁbrosis and the
level of inﬂammation [27]. We will discuss both invasive
andnoninvasive meansofassessing andstaging patientswith
NAFLD, including information about the characteristics of
each method.
2.1. Clinical Features. The majority of patients diagnosed
with NAFLD are asymptomatic [8, 28]. When present,
clinical symptoms and physical ﬁndings are nonspeciﬁc and
unreliable for diagnosing and assessing disease severity in
patients with NAFLD. Patients might have hepatomegaly,
general malaise, abdominal discomfort, vague right upper
quadrant abdominal pain, nausea, and other nonspeciﬁc
symptoms referred to the gastrointestinal tract. Clini-
cal examination may reveal ascites, splenomegaly, spider
angiomas, palmar erythema, caput medusae, and jaundice
in a small percentage of patients who present with NASH-
related cirrhosis [8, 28]. The features more consistently
found to be associated with disease severity include obesity,
older age, diabetes, and hypertension [11].
2.2. Common Biomarkers. There is no single biochemical
markerthatcanconﬁrmadiagnosisofNAFLDordistinguish
between steatosis, NASH, and cirrhosis [8]. Although mildly
elevated serum aminotransferase levels are the primary
abnormality seen in patients with NAFLD, liver enzymes
may be normal in up to 78% of patients with NAFLD
[12, 29]. Additionally, the entire histological spectrum of
NAFLD can be observed in patients with normal alanine
aminotransferase (ALT) values [30, 31]. Therefore, liver
enzyme levels are not sensitive for the diagnosis of NAFLD.
The elevations in ALT and aspartate aminotransferase (AST)
are typically mild when present and are usually not greater
than four times the upper limit of normal [29, 32]. The ratio
of AST/ALT is usually less than 1 in patients who have either
no or minimal ﬁbrosis, although this ratio may be greater
than 1 with the development of cirrhosis [33].
Gamma-glutamyltransferase (GGT) in the serum is
frequently elevated in patients with NAFLD, and it has been
reported to be associated with increased mortality [34, 35].
However,thediagnosisofNAFLDcannotbemadeusingonly
GGT.IncreasedserumGGTlevelshavealsobeenshowntobe
associated with advanced ﬁbrosis in NAFLD patients, with
a study of 50 NAFLD patients demonstrating an area under
the receiver operating characteristic curve (AUROC) of 0.74
for the prediction of advanced ﬁbrosis. Using a cutoﬀ serum
GGT value of 96.5 U/L, GGT predicted advanced ﬁbrosis
with 83% sensitivity and 69% speciﬁcity [36]. Alkaline
phosphataseissometimes slightlyelevated,butitisrarelythe
only liver function test abnormality [37].
When portal hypertension and hepatic synthetic dys-
function are present with cirrhosis, hypoalbuminemia, hy-
perbilirubinemia, thrombocytopenia, and a prolonged pro-
thrombin time may be seen [28]. Furthermore, an elevated
f e r r i t i nl e v e lh a sb e e nr e p o r t e di nu pt o5 0 %o fN A S H
patients, and elevated transferrin saturation in approxi-
mately 10% [33]. However, these ﬁndings do not appear to
correlate with an elevated iron concentration in the liver,
and the role of hepatic iron in the pathogenesis of NASH is
unclear [38].
2.3. Novel Biomarkers. Several investigators have proposed
the measurement of other novel biomarkers to support
the diagnosis of NAFLD, but these investigations have
been limited by their lack of reproducibility or inability to
accurately distinguish simple steatosis from more advancedExperimental Diabetes Research 3
inﬂammation and ﬁbrosis [8]. Ideally, novel biomarkers
should be helpful for monitoring the progression of NAFLD
over time, its response to therapeutic interventions, and for
determining the prognosis of the disease. However, there
is no such a biomarker available at present [10]. These
novel potential biomarkers are shown herein, being classiﬁed
by the key mechanisms of NASH pathogenesis that they
are associated with, including “inﬂammation,” “ﬁbrosis,”
“oxidative stress,” and “hepatocyte apoptosis”.
2.3.1. Inﬂammation. A chronic low-grade inﬂammatory
state characteristic of patients with metabolic syndrome has
been extensively associated with the development of steatosis
as well as liver damage in NAFLD [39, 40]. Inﬂammatory
mediators have also been investigated as potential diagnostic
tools. NAFLD is associated with an increase in tumor
necrosis factor alpha (TNF-α) and decreased adiponectin,
and this cytokine imbalance may play an important role
in the development of NASH [41–46]. Several groups
have reported the circulating levels of these cytokines in
the blood from patients with NAFLD to correlate with
NASH. Moreover, the TNF-α levels were also observed to
correlate with the severity of inﬂammation and ﬁbrosis
[41, 47]. However, there are still limited data available on
the accuracy and clinical usefulness of these markers for
the noninvasive diagnosis of NASH [10]. Shimada et al.
reported that the serum adiponectin was signiﬁcantly lower
in patients with early-stage NASH than in those with simple
steatosis. Adiponectin had an AUROC of 0.765, sensitivity
of 68%, and speciﬁcity of 79% for distinguishing early-stage
N A S H ,u s i n gac u t o ﬀ value of ≤4.0μg/mL. In this study,
the combination of the serum adiponectin level with the
HomeostasisModelAssessment-InsulinResistance(HOMA-
IR) level (cutoﬀ value ≥3.0) and type IV collagen 7S (cutoﬀ
value ≥5.0ng/mL) demonstrated a sensitivity of 94% and
a speciﬁcity of 74% for diagnosing NASH [48]. In another
report, using adiponectin and HOMA-IR levels, the AUROC
for distinguishing between steatohepatitis and steatosis was
0.79[43].However,therelationshipbetweentheadiponectin
levels and the severity of hepatic ﬁbrosis still remains to be
established [49, 50].
The inﬂammatory marker, C-reactive protein (CRP),
lacks speciﬁcity for hepatic inﬂammation and has demon-
strated mixed results for NASH. There was a signiﬁcant
increase in high-sensitivity CRP levels in NASH patients
compared with controls in some studies [51, 52], and no
signiﬁcant diﬀerence in another [53]. Interleukin-6 (IL-6)
has also been shown to be elevated in NASH [54]. IL-6 had
an AUROC of 0.817 for distinguishing NASH from simple
steatosis[55].TheIL-6levelswerealsoindependentlyrelated
to ﬁbrosis [56].
Several authors have reported a relationship to exist
between leptin, a hormone secreted from adipose tissue,
and liver histology. However, the leptin levels have not been
shown to correlate with the degree of steatosis or ﬁbrosis,
although some studies have previously reported patients
with steatosis and NASH to demonstrate elevated levels of
leptin [57–59]. In a recent study, using the combination of
HOMA-IR with the adiponectin/leptin ratio, the AUROC
was 0.82 for distinguishing between NASH and simple
steatosis [56].
Other inﬂammatory markers, such as CC-chemokine
ligand 2 (CCL-2) and hyaluronic acid (HA), have also been
showntobeelevatedinpatientswithNASH[60–62].HAwill
be described in the next section.
2.3.2. Fibrosis. During the evaluation of NAFLD, it is
important to consider the level of ﬁbrosis. Potential ﬁbrosis
biomarkers include type IV collagen 7S domain and HA.
Sakugawa et al. reported that these two biomarkers were
able to exclude advanced ﬁbrosis, with AUROCs of 0.82
and 0.80, and negative predictive values (NPV) of 84% and
78%, respectively, in a cohort of 112 NAFLD cases. These
biomarkers also demonstrated positive predictive values
(PPV) of 86% and 92% and AUROCs of 0.83 and 0.80 for
discriminating between NASH and simple hepatosteatosis
[63]. In another report, the AUROC for type IV collagen
7S domain and HA were 0.767 and 0.754, respectively, for
the detection of advanced ﬁbrosis in NASH cases, although
a multiple regression analysis revealed that only the type
IV collagen 7S domain was independently associated with
advanced ﬁbrosis in this study [64]. In patients with NAFLD,
evaluatingtheHAlevelswasfoundtobeusefulforpredicting
severe ﬁbrosis, with an AUC of 0.9, with a cutoﬀ value of
serum HA of 46.1ug/l, yielding a sensitivity of 85% and
a speciﬁcity of 80% [61]. Furthermore, the platelet count
alone was demonstrated to be an independent predictor of
cirrhosis, with an AUROC of 0.98 in NAFLD. In this study,
HA had an AUROC of 0.97 for detecting severe ﬁbrosis, with
a lower AUROC of 0.87 shown for type IV collagen. Serum
laminin, which is an extracellular matrix component, was
also shown to have an accuracy of 87%, sensitivity 82%,
speciﬁcity 89%, PPV 82%, and NPV 89% for prediction of
ﬁbrosis in NAFLD [65].
2.3.3. Oxidative Stress. Oxidative stress is one of the key
mechanisms responsible for liver damage and disease pro-
gression in NAFLD [66, 67]. To date, many markers of
oxidative stress, including lipid peroxidation products, vita-
min E levels, and copper-to-zinc superoxide dismutase and
glutathione peroxidase (GSH-Px) activity, have been inves-
tigated to determine whether they can be used as surrogate
markers of NASH. However, mixed results were demon-
strated [68–70], and there is no clear answer at present.
Thioredoxin (TRX) is induced by many oxidative
stresses. A signiﬁcant elevation of the serum TRX levels was
demonstrated in patients with NASH in comparison to those
with simple steatosis and healthy controls [71, 72].
2.3.4. Hepatocyte Apoptosis. Apoptosis plays an important
role in the liver injury observed in NAFLD [73–77]. Re-
cently, a speciﬁc byproduct of apoptosis in hepatocytes,
caspase-generated cytokeratin-18 (CK-18) fragments, has
been shown to be signiﬁcantly elevated in patients with
NASH compared with subjects with fatty liver or healthy
controls, with an AUC of 0.93 for predicting NASH [78].
Additionally, Feldstein et al. demonstrated that the plasma
CK-18 levels measured using ELISA were signiﬁcantly higher4 Experimental Diabetes Research
in patients with biopsy-proven NASH than in those with a
borderline diagnosis and normal controls, with an AUROC
of 0.83 for NASH diagnosis, in a US multicenter validation
study. CK-18 was an independent predictor of both NASH
and the severity of disease [79]. Other reported results [78,
80–85] also suggest that CK-18 can be a potentially useful
biomarker for the diagnosis and diﬀerentiation of NASH
from simple hepatosteatosis. CK-18 levels were observed
to decrease after bariatric surgery in NASH patients [86].
Therefore,CK-18fragmentsmightbeusefulforassessingthe
response to therapy for NASH.
The plasma homocysteine levels [87], serum prolidase
enzyme activity (SPEA) catalysis [88], plasma pentraxin 3
levels [89], and tissue polypeptide speciﬁc antigen [90]a r e
other novel biomarkers for a diagnosis of NASH, however,
additional studies are needed to determine their potential for
clinical use.
2.4. Panels of Markers. Several studies have been performed
todevelopnoninvasivediagnosticpanelsandscoringsystems
that might support the identiﬁcation of liver steatosis and
the diagnosis NASH and to determinate severity of ﬁbrosis,
in order to replace the invasive standard liver biopsy. Such
scoring systems may potentially represent a more accurate
evaluation of global liver ﬁbrosis severity, because the
distribution of ﬁbrosis throughout the liver can be uneven
in NAFLD [27].
2.4.1. Panel Markers for the Identiﬁcation of Liver Steatosis.
TheNAFLD liverfatscoreincludes, asvariables, thepresence
of metabolic syndrome and T2DM, fasting serum insulin,
serum AST, and the AST/ALT ratio. This score has an
AUROC of 0.86-0.87 to predict liver steatosis, and addition
of the genetic information to the score slightly improved
the AUROC. Using the same variables, a liver fat equation
was developed, from which the liver fat percentage could be
estimated [91].
Bedogni et al. developed the fatty liver index (FLI),
which uses the body mass index (BMI), waist circumference,
triglyceride level, and GGT in the general population with
low prevalence of T2DM. This index varies from 0 to 100,
and the AUROC was 0.84 to detect liver steatosis [92]. They
also reported that the lipid accumulation product (LAP),
based on the measurement of waist circumference and the
triglyceride level, proved to be a simple and reasonably
accuratepredictorofultrasonographicliversteatosis,withan
A U R O Co f0 . 8[ 93].
Moreover, the visceral adiposity index (VAI), which uses
the BMI, waist circumference, and levels of triglycerides and
high-density lipoprotein (HDL) cholesterol, is thought to be
capable of indicating both the fat distribution and function.
This index was reported to be associated with liver steatosis
in patients with chronic hepatitis C, making it a candidate
predictor of NAFLD [94].
2.4.2.PanelMarkersforNASHDiagnosis. TheHAIR(Hyper-
tension, ALT, and Insulin Resistance) score was designed
to predict a NASH diagnosis, and includes a combination
of the presence of hypertension, elevated ALT, and insulin
resistance. The presence of at least 2 parameters predicted
NASH with both a high sensitivity and speciﬁcity [95].
Palekar et al. generated a clinical model to distinguish
NASH from simple steatosis by combining 6 diﬀerent var-
iables including age, gender, AST, BMI, the AST/ALT ratio,
and serum HA [96]. The AUROC for this model was 0.76.
The presence of 3 or more of these factors had a sensitivity
and speciﬁcity for a NASH diagnosis of 74% and 66%,
respectively.
Moreover, a simpliﬁed model has also been proposed
using a logistic regression analysis with only AST and a
diagnosis of diabetes, which was able to distinguish NASH
from fatty liver with or without nonspeciﬁc inﬂammation in
bariatric surgery patients with similar accuracy as the panels
d e s c r i b e di np r e v i o u ss t u d i e s[ 97]. These panels should be
thus investigated to validate them in diﬀerent populations.
TheNashTestcombines13biochemicalandclinicalvari-
ables to predict the presence of NASH, achieving speciﬁcity,
sensitivity, PPV, and NPV of 94%, 33%, 66%, and 81%,
respectively [98]. Pelekar et al. combined 8-epi-PGF2α,T G F -
β,HA,andadiponectininamodelthatpredictedNASHwith
favorable sensitivity of 73.7%, speciﬁcity of 65.7%, PPV of
68.2%, and a NPV of 68.2% [96].
2.4.3. Panel Markers for Fibrosis in NAFLD. The FibroTest
is a validated set of markers for the quantitative assessment
of ﬁbrosis, and it includes α2-macroglobulin, apolipoprotein
A-I, haptoglobin, total bilirubin, GGT, and ALT [99]. The
mean standardized AUROC was 0.84 for advanced ﬁbrosis
in NAFLD patients after correcting for age and gender in one
meta-analysis.
The NAFLD ﬁbrosis score (NFS) is generated using a
panel including six variables of age, hyperglycaemia, BMI,
platelet count, albumin, and AST/ALT ratio (AAR), which
was created using a large cohort of biopsy-proven NAFLD
patients [100]. McPherson et al. reported the NFS to dem-
onstrate an AUROC of 0.81 with NPV 92% and PPV 72%
f o rt h ed e t e c t i o no fa d v a n c e dﬁ b r o s i s[ 101]. Cal` es et al.
demonstrated an AUROC of 0.884 for signiﬁcant ﬁbrosis,
0.932 for severe ﬁbrosis, and 0.902 for cirrhosis [102]. In a
recent meta-analysis, NFS showed AUROC, sensitivity, and
speciﬁcity of 0.85, 0.90, and 0.97 for the identiﬁcation of
NASH with advanced ﬁbrosis [103].
The original ELF (European Liver Fibrosis) test is a
panel of automated immunoassays to detect three markers:
HA, tissue inhibitor of metalloproteinase 1 (TIMP1), and
aminoterminal peptide of procollagen III (P3NP), used in
combination with age [104]. The simpliﬁed ELF panel ex-
cludedage,butdidnotchangethediagnosticperformanceof
the panel. The addition of ﬁve markers, including the BMI,
presence of diabetes/impaired fasting glucose, AAR, platelet
count, and albumin concentration, to the ELF test improved
its diagnostic accuracy, with AUROCs of 0.98, 0.93, and
0.84 for the diagnosis of severe, moderate and no ﬁbrosis,
respectively [105].
The BARD score is a simple scoring system that can be
used as a predictive tool in assessing ﬁbrosis in patients with
NAFLD. It combines three variables; the BMI, AAR, andExperimental Diabetes Research 5
the presence of diabetes [106]. A study of the BARD score
in 138 patients with biopsy-proven NAFLD demonstrated an
AUROC of 0.67, with sensitivity, speciﬁcity, PPV, and NPV
of 51%, 77%, 45%, and 81%, respectively [107].
The AST-to-platelet ratio index (APRI) was initially used
as a marker of ﬁbrosis in patients with hepatitis C [108].
Using this score, Cal` es et al. reported an AUROC of 0.866
for signiﬁcant ﬁbrosis, 0.861 for severe ﬁbrosis, and 0.842
for cirrhosis in a study of NAFLD subjects [102], although
signiﬁcantly lower values were obtained in other studies
[101, 109, 110].
The AAR [111] is easily calculated using two laboratory
liverfunctiontests.NotonlyistheAARusedasanindividual
marker, but it is also a component of several other ﬁbrosis
scoring systems, including the NFS and BARD score. Using
a cut-oﬀ of 0.8, AAR alone showed an AUROC of 0.83, with
a sensitivity of 74%, speciﬁcity of 78%, and a NPV of 93%
for the diagnosis of advanced ﬁbrosis in NAFLD [101]. In
another study, a combination of serum AST, ALT, and the
AAR had an AUROC of 0.59 for predicting steatosis, but
was able to predict cirrhosis with an AUROC of 0.81. How-
ever, the addition of demographic data, comorbidities, and
several other routinely measured laboratory tests increased
the AUROCs to 0.79 for NASH and 0.96 for cirrhosis
[112].
The components of the FIB-4 test are age with three bio-
chemical values; the platelet count, ALT, and AST, to detect
ﬁbrosis [113]. In NAFLD patients, the FIB-4 demonstrated
anAUROCof0.86,sensitivityof85%,speciﬁcityof65%,and
an NPV of 95% for the diagnosis of advanced ﬁbrosis [101].
Interestingly,inacomparisonofseveralmarkersofﬁbrosisin
NAFLD subjects, FIB-4 had the highest AUROC (0.802) for
the diagnosis of advanced ﬁbrosis, followed by the AUROCs
for the NAFLD ﬁbrosis score, AAR, APRI, and AST: platelet
ratio and BARD score of 0.768, 0.742, 0.73, 0.72 and 0.70,
respectively [114].
The FibroMeter combines seven variables: age, weight,
fasting glucose, AST, ALT, ferritin, and the platelet count
[115]. In a study of 235 NAFLD patients, it had AUROCs
of 0.943 for signiﬁcant ﬁbrosis, 0.937 for severe ﬁbrosis, and
0.904 for cirrhosis, respectively. The sensitivity, speciﬁcity,
PPV, and NPV of the FibroMeter for diagnosing signiﬁcant
ﬁbrosis were 79%, 96%, 88%, and 92% [102].
2.5. Imaging. Although many imaging tools have been as-
sessed in NAFLD subjects, their main focus has been the
quantiﬁcation of liver fat. The results of these imaging tests
cannot be used to diﬀerentiate between the histological
subtypes of simple steatosis or NASH, nor can they be used
to stage the degree of ﬁbrosis [116, 117]. In this section,
we explain each imaging modality, while referring to the
detection of hepatosteatosis, steatohepatitis, and ﬁbrosis.
2.5.1. Ultrasonography (US). US is currently the most com-
mon method for screening asymptomatic patients with el-
evated liver enzymes and suspected NAFLD. US ﬁndings
of fatty liver include hepatomegaly, diﬀuse increases in the
echogenicity of the liver parenchyma, and vascular blunting.
Nonsteatotic hepatic parenchyma exhibits an echotexture
similar to that of renal parenchyma, but becomes “brighter”
when inﬁltrated with fat [118]. This hepatorenal contrast
can be used for detecting hepatosteatosis [118, 119]. A re-
cent study by Palmentieri et al. of 235 patients undergoing
US with liver biopsy showed a sensitivity, speciﬁcity, PPV,
and NPV of 91%, 93%, 89%, and 94%, respectively, for
predicting at least 30% steatosis. However, bright liver con-
trast was not associated with ﬁbrosis in this study [120].
US is easily performed and has a low cost, but it also
has some limitations. It is operator dependent and subject
to signiﬁcant intra- and interobserver variability [121]. It is
impossible for US to provide quantitative information about
thedegreeoffataccumulation.ThesensitivityofUStodetect
steatosis decreases with a degree of fat inﬁltration less than
30% [122]. In obese patients, sensitivity lower than 40% has
been reported to detect hepatosteatosis [123]. Finally, US has
failed to prove eﬃcacious for the detection of inﬂammation
and ﬁbrosis, therefore, it cannot be utilized to diagnose
NASH and hepatic ﬁbrosis [10]. In a recent study, however,
Iijima et al. used an ultrasound contrast agent (Levovist;
Sherling, Berlin) to distinguish between simple steatosis and
NASH. Levovist contains galactose and palmitic acid and is
taken up by hepatocytes [124]. These moieties participate in
the sugar and fat metabolism [125] .T h eu p t a k eo fL e v o v i s t
is observed to signiﬁcantly decrease in NASH patients, thus
correlating with ﬁbrosis rather than steatosis [124]. Larger
studies are needed to evaluate contrast US for use in the
diagnosis of NASH and advanced ﬁbrosis.
2.5.2. Computed Tomography (CT). CT allows for a more
quantitative assessment with measurement of liver attenu-
ation in Hounsﬁeld units (HUs) compared to US, but the
information about liver attenuation is not uniform when
reported by radiologists. It appears that noncontrast CT
scanning is more useful for detecting steatosis than contrast-
enhanced scans [126]. Unenhanced CT is more commonly
used than enhanced CT [127], and several techniques for
determiningtheappropriateCTvaluesincludemeasurement
of hepatic attenuation only [128, 129] and normalization
of hepatic attenuation by splenic attenuation, reporting
the diﬀerence in attenuation between the liver and spleen
[127, 129] and the ratio of these values [129, 130]. The
attenuationofthespleenisapproximately8–10HUslessthan
the liver in normal subjects [127]. With unenhanced CT, an
attenuationoftheliverislessthan40HUs[131],oraliver-to-
spleen attenuation diﬀerence greater than −10HUs is highly
predictive of hepatosteatosis [127]. In addition, a liver-to-
spleen ratio of less than 1 is sometimes used to diagnose
fatty liver [127, 130]. CT has been demonstrated to be useful
for diagnosing >30% steatosis by the use of liver: spleen
attenuationratios;themethodhasasensitivityof73%–100%
and a speciﬁcity of 95%–100% [29, 132]. The accuracy of
unenhanced CT is greatly reduced when there is a lesser
degree of steatosis [129]. Other pathologies, such as hepatic
siderosis, may also alter attenuation values, thus leading to a
misdiagnosis [133, 134]. In longitudinal studies with young
subjects, the radiation exposure associated with CT limits its
use [133].6 Experimental Diabetes Research
2.5.3. Magnetic Resonance Imaging (MRI) and Proton Mag-
netic Resonance Spectroscopy (MRS). A good correlation has
been reported between MRI, US, and histology in patients
with NAFLD [135]. Among these modalities, MRI has been
shown to most accurately detect lower levels of steatosis
than those detected by US and CT. Fatty changes are as-
sessed by diﬀerential chemical shifts between fat and water
detected by MRI. MRI was able to detect steatosis of level
down to 3% [135]. A variant of MRI, MRS, has also been
shown to reliably measure steatosis [136]. Szczepaniak et
al. used proton MRS to measure hepatic triglyceride levels
(HTGC) in 375 subjects [2]. In this study, 34.3% of the
2,287 participants studied had HTGC >5%, a level deemed
diagnostic of hepatic steatosis. MRI and MRS have a higher
diagnostic accuracy than US or CT, and MRS can be
used to quantify hepatic steatosis. However, none of these
imaging techniques have suﬃcient sensitivity and speciﬁcity
for staging the disease, and therefore cannot distinguish
between fatty liver and NASH with or without ﬁbrosis [116].
Moreover, these tools are more expensive and less accessible
than other imaging modalities.
2.5.4. Transient Elastography. Transient elastography (Fi-
broscan, Echosens, Paris, France) is a non-invasive method
of assessing liver ﬁbrosis which can be performed at the
bedside or in an outpatient clinic. It uses ultrasound-based
technology to measure liver stiﬀness. Although Fibroscan
is less well validated in NAFLD, in a study of 97 NAFLD
patients, AUROCs for the diagnosis of signiﬁcant ﬁbrosis,
severe ﬁbrosis, and cirrhosis were reported to be 0.88,
0.91, and 0.99, respectively [137]. Another study including
246 NAFLD patients showed AUROCs for the diagnosis of
moderate ﬁbrosis, bridging ﬁbrosis, and cirrhosis of 0.84,
0.93, and 0.95, respectively [138].
The combination of transient elastography with one or
more of the serum marker panels might be a potential
approach for the non-invasive measurement of ﬁbrosis in
NAFLD [10].
2.6. Histology. The histological spectrum of NAFLD ranges
from simple steatosis through steatohepatitis to ﬁbrosis
and cirrhosis [139]. Liver biopsy is the gold standard for
diagnosis and has the additional beneﬁt of distinguishing
between NASH and simple steatosis, thus allowing for
the staging of the degree of ﬁbrosis, which also provides
helpful information regarding prognosis and may inﬂuence
the clinical management of NAFLD [116, 140, 141]. Liver
biopsies can also exclude other liver diseases, such as drug-
induced hepatotoxicity, Wilson disease and autoimmune
hepatitis [11, 142]. Hence, although the diagnosis of NAFLD
can usually be conﬁrmed by only a combination of history,
serological analyses, and abdominal imaging, liver tissue is
needed to determine the severity of NAFLD and to rule out
other possible liver diseases [8].
ThehistologicalchangesinNAFLDaremainlyparenchy-
mal and appear in a perivenular location, although portal
and periportal lesions may also be present [139]. Simple
steatosis is usually macrovesicular, resulting from the accu-
mulation of triglycerides within hepatocytes [143]. NASH
requires evidence of lobular inﬂammation, which usually
consists of a mixed mononuclear and neutrophil inﬁltration.
Additionally, hepatocyte ballooning, necrosis, and Mallory’s
hyaline might be present [144]. Mitochondrial abnormalities
may also occur in NASH, but rarely in simple steatosis [145].
As the disease progresses, the typical histological features of
steatosis and inﬂammation frequently disappear and may
become completely absent in patients with cirrhosis [146].
Thus, many cases of cryptogenic cirrhosis may be caused
by NASH cirrhosis [147–149]. Hepatocellular carcinoma is
a complication of NASH-related cirrhosis [117, 150]a n d
also of precirrhotic NAFLD [151, 152]. Other histological
ﬁndings characteristic of NAFLD in T1DM patients includes
diabetic hepatosclerosis and glycogenic hepatopathy [25,
153].
The NAFLD Activity Score (NAS) is used for the
histological assessment of NAFLD to distinguish steatosis
fromNASHinclinicaltrials[154].NASprovidesacomposite
score based on the degree of steatosis, lobular inﬂammation,
and hepatocyte ballooning. A score greater than or equal
to 5 is likely to represent NASH, a score of 0–2 is unlikely
to represent NASH, and a score of 3 or 4 is indeterminate.
The NAS does not include ﬁbrosis, and ﬁbrosis is reported
separately,onascalefrom0(withoutﬁbrosis)to4(cirrhosis)
[154]. However, it should be noted that the diagnosis of
deﬁnite liver steatosis based on evaluations of the patterns
on liver biopsy does not always correlate with the threshold
valuesofthesemiquantitativeNAS,whichwasdevelopedasa
tool to measure changes in NAFLD during therapeutic trials
[155].
Limitations of Liver Biopsy. There are several limitations
associated with liver biopsy. Liver biopsy, being an invasive
procedure, has a small risk of complications including pain,
bleeding, and, rarely, death. Next, since only a very small
portion of the liver is obtained from the needle liver biopsy
as a tissue sample (1/50,000 of the total mass of the liver),
the biopsy is prone to signiﬁcant sampling error [156, 157],
especially regarding such features as ﬁbrosis, which are
often not uniformly distributed. Finally, another important
limitation of liver biopsy is the fact that the histological
analysis remains subjective, is inﬂuenced by the skill and
experience of the reading pathologist, and is thus prone to
intra- and interobserver variability [154, 158].
3. Conclusion
At present, NAFLD is the most common cause of ele-
vated LFT results, after the commonly investigated causes
have been excluded. NAFLD and T2DM frequently coexist
because of their similar pathogenic abnormalities. As both
T2DM and NAFLD are related to adverse outcomes of the
other, the diagnosis and evaluation of fatty liver is an im-
portant part of the management of diabetes. Noninvasive
methods are favorable ways to support a diagnosis of hepa-
tosetaotsis, but accurate histopathological ﬁndings and stag-
ing of ﬁbrosis cannot be achieved without a liver biopsy. It
is important to determine whether NASH and liver ﬁbrosisExperimental Diabetes Research 7
are present, because close monitoring and followup are
necessary for these patients. Therefore, a liver biopsy re-
mains the gold standard for the diagnosis and evaluation of
NAFLD. However, new investigations on the pathogenesis
of the disease progression in NAFLD might result in the
development of useful biomarkers that could provide a re-
liable noninvasive alternative to liver biopsy.
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